Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Validation of the care partner stress scale in the CAN-PROTECT study.

Journal of Alzheimer's disease : JAD·2026
Same author

The association between autistic traits and trajectories of anxiety in middle-aged and older adults: an 8-year growth mixture model analysis.

Nature. Mental health·2026
Same author

Mild Behavioural Impairment and Everyday Functioning in Cognitively Unimpaired Older Adults: Evidence From the CAN-PROTECT Study.

Journal of geriatric psychiatry and neurology·2026
Same author

Cross-sectional and longitudinal associations of self-perceptions of aging with physical activity in multimorbidity: The role of depressive symptoms.

Archives of gerontology and geriatrics·2026
Same author

Stakeholder perspectives on the potential benefits, risks, and implications of an interactive cognitive monitoring app for the identification and monitoring of cognitive decline in adults at risk of dementia.

BMC health services research·2026
Same author

Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada.

International journal of geriatric psychiatry·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jun 3, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

La enfermedad de Alzheimer es la enfermedad de Alzheimer.

Clive Ballard1, Serge Gauthier, Anne Corbett

  • 1Wolfson Centre for Age-Related Diseases, King's College London, London, UK. clive.ballard@kcl.ac.uk

Lancet (London, England)
|March 5, 2011
PubMed
Resumen
Este resumen es generado por máquina.

La enfermedad de Alzheimer afecta a millones de personas en todo el mundo, lo que requiere una mejor comprensión de sus causas, diagnóstico y factores de riesgo. Esta visión general destaca la evidencia reciente y discute posibles estrategias para la reducción del riesgo.

Más Videos Relacionados

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Videos de Experimentos Relacionados

Last Updated: Jun 3, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Área de la Ciencia:

  • Neurología Neurología.
  • Salud Pública La salud pública.
  • Epidemiología La epidemiología.

Sus antecedentes:

  • La enfermedad de Alzheimer (EA) es una de las principales causas de demencia, que afecta a un estimado de 24 millones de personas en todo el mundo.
  • La AD plantea un desafío significativo para la salud pública, lo que subraya su estatus como una prioridad de investigación.
  • Los tratamientos actuales manejan los síntomas de la EA, pero las terapias modificadoras de la enfermedad requieren una comprensión más profunda de la patogénesis.

Objetivo del estudio:

  • Proporcionar una visión general de la evidencia reciente sobre la enfermedad de Alzheimer (EA).
  • Para discutir la epidemiología, la patogénesis, el diagnóstico y el tratamiento de la enfermedad de Alzheimer.
  • Explorar estrategias potenciales de reducción de riesgos para la enfermedad de Alzheimer y el deterioro cognitivo.

Principales métodos:

  • Revisión de la literatura de las pruebas recientes.
  • Síntesis de la comprensión actual de la patogénesis de la EA.
  • Análisis de los avances en el diagnóstico, incluyendo biomarcadores y neuroimagen.
  • Examen de los factores de riesgo y protectores identificados para la EA y la demencia.

Principales resultados:

  • Avances significativos en la comprensión del riesgo de EA y los factores de protección.
  • El desarrollo continuo de métodos de diagnóstico, con la necesidad de un consenso de biomarcadores.
  • La evidencia sugiere el potencial de las intervenciones para reducir el riesgo de EA.
  • Los tratamientos autorizados ofrecen alivio sintomático pero no modificación de la enfermedad.

Conclusiones:

  • La investigación adicional es crucial para desarrollar tratamientos modificadores de la enfermedad para la enfermedad de Alzheimer.
  • Se necesitan herramientas de diagnóstico mejoradas, incluidos paneles de biomarcadores validados.
  • Comprender y mitigar los factores de riesgo es clave para reducir la carga de la enfermedad de Alzheimer y la demencia.